Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Overview: A biopharmaceutical company developing cell-based therapeutics for the central nervous system (CNS) and liver. The company operates in one segment and has incurred significant operating losses since inception. Key programs include the HuCNS-SC product candidate for neuronal ceroid lipofuscinosis (NCL) and Pelizeaus-Merzbacher Disease (PMD).
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Revenue | $56,603 | $17,350 |
| Net Loss | $(9,281,554) | $(6,544,989) |
| Net Loss Per Share (Basic & Diluted) | $(0.10) | $(0.08) |
| Cash and Cash Equivalents | $34,057,052 | $9,759,169 (Beginning of period) |
| Total Assets | $42,162,864 | $41,230,340 |
| Total Liabilities | $21,832,960 | $19,421,355 |
| Stockholders' Equity | $20,329,904 | $21,808,985 |
| Operating Cash Flow | $(5,781,631) | $(7,291,366) |
| Financing Cash Flow | $6,875,383 | $(36,773) |
Debt and Liquidity: The company holds approximately $34.1 million in cash and cash equivalents. Total debt obligations include capital lease obligations ($165,926) and bond payables ($972,917). A significant liability is the fair value of warrant liability, which increased to $11.2 million.
Material Changes vs. Prior Period
- Revenue Increase: Revenue increased 226% to $56,603, primarily driven by a $31,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for liver disease research.
- Net Loss Expansion: Net loss increased by approximately $2.7 million. This was largely due to a non-cash charge of $2.755 million representing the change in fair value of the warrant liability.
- Operating Expenses: Total operating expenses remained relatively flat ($6.98 million vs. $6.91 million). Research and Development (R&D) expenses decreased by 6% due to the completion of the NCL Phase I trial. General and Administrative (G&A) expenses increased by 13%, driven by professional fees related to the acquisition of Stem Cell Sciences Plc (SCS).
- Investment Activity: The company sold marketable securities (ReNeuron shares) for a realized gain of $398,000.
Outlook, Risks, and Unusual Items
- Acquisition: On April 1, 2009 (subsequent to the reporting period), the company acquired substantially all operating assets and liabilities of Stem Cell Sciences Plc (SCS) for 2.65 million shares of common stock and the waiver of $709,000 in loans. This expands the company's portfolio to include embryonic stem cells and iPS cells.
- Warrant Liability: The company recorded a $2.76 million loss due to the revaluation of warrants issued in November 2008. This is a non-cash item but significantly impacts net loss.
- Wind-Down Expenses: The company maintains a reserve of approximately $5.34 million for the exit costs of its former Rhode Island facility. Expenses for this facility fluctuate based on sublease occupancy rates.
- Liquidity Risk: Management states that existing capital resources may not be sufficient to fund operations beyond the next twelve months. The company relies on equity offerings, debt, and grants to sustain operations.
- Legal Proceedings: Ongoing patent infringement litigation against Neuralstem, Inc. remains a significant contingency. The outcome is uncertain and could impact the company's intellectual property portfolio.
- Guidance: The company does not provide specific financial guidance but expects to incur substantial operating losses in the foreseeable future as it advances clinical trials and integrates the SCS acquisition.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $34 million cash balance against the projected burn rate, considering the integration costs of the SCS acquisition.
- Warrant Liability Volatility: Monitor the fair value of the $11.2 million warrant liability, as fluctuations will continue to impact reported net loss without affecting cash flow.
- Rhode Island Facility: Assess the progress of subleasing the former Rhode Island facility to reduce the $5.3 million wind-down reserve and associated cash outflows.
- Patent Litigation: Review updates on the Neuralstem, Inc. litigation, as a negative outcome could invalidate key patents essential to the business model.
- Capital Raising: Confirm the status of the universal shelf registration statement and the ability to raise additional capital in the current market environment.